Abstract
What is known and objective: Acquired long QT syndrome secondary to drug-induced QT prolongation and torsades de pointes has been reported for antiviral drugs. However, no studies have reported an association between corrected QT (QTc) prolongation and antiviral therapy in patients with novel coronavirus disease (COVID-19).
Case description: We present two cases from our institution in which patients with COVID-19 experienced QTc prolongation during treatment with antiviral therapy. Lopinavir/ritonavir, together with gender and drug-drug interactions, may have contributed to the induction of QTc prolongation in those patients.
What is new and conclusion: Co-administration of QT-prolonging medications and drugs interfering with the metabolism of those medications must be considered in patients with COVID-19. Careful analysis of electrocardiograms for QTc duration should be performed at baseline and during antiviral therapy to identify individuals at high risk of arrhythmias.
Keywords: COVID-19; QTc interval prolongation; drug interactions; lopinavir/ritonavir.
【저자키워드】 COVID-19, Lopinavir/ritonavir, Drug interactions, QTc interval prolongation, 【초록키워드】 Treatment, coronavirus disease, antiviral therapy, Lopinavir/ritonavir, antiviral drugs, Lopinavir, Ritonavir, Gender, drug, novel coronavirus disease, metabolism, Novel coronavirus, Drug-drug interactions, QT prolongation, electrocardiogram, Patient, medication, Arrhythmias, patients, QTc, association, Drug interactions, QTC prolongation, Long QT syndrome, Analysis, Electrocardiograms, high risk, secondary to, during treatment, torsades de pointes, QTc interval, individual, syndrome, identify, performed, reported, contributed, Acquired, baseline, patients with COVID-19, torsades de pointe, 【제목키워드】 antiviral therapy, two COVID-19 patient,